Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI
Irbesartan y enfermedad renal crónica avanzada de causa no diabética. Estudio comparativo con IECAS
Leído
19124
Vecesse ha leído el artículo
8278
Total PDF
10846
Total HTML
Información del artículo
ISSN: 20132514Idioma original: Inglés
Datos actualizados diariamente
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 11 | 265 | 35 | 300 |
| 2025 10 | 260 | 41 | 301 |
| 2025 9 | 176 | 32 | 208 |
| 2025 8 | 202 | 122 | 324 |
| 2025 7 | 215 | 183 | 398 |
| 2025 6 | 131 | 130 | 261 |
| 2025 5 | 170 | 52 | 222 |
| 2025 4 | 136 | 60 | 196 |
| 2025 3 | 173 | 101 | 274 |
| 2025 2 | 137 | 60 | 197 |
| 2025 1 | 136 | 64 | 200 |
| 2024 12 | 91 | 76 | 167 |
| 2024 11 | 93 | 96 | 189 |
| 2024 10 | 100 | 103 | 203 |
| 2024 9 | 80 | 89 | 169 |
| 2024 8 | 96 | 110 | 206 |
| 2024 7 | 68 | 74 | 142 |
| 2024 6 | 111 | 105 | 216 |
| 2024 5 | 101 | 100 | 201 |
| 2024 4 | 73 | 68 | 141 |
| 2024 3 | 69 | 97 | 166 |
| 2024 2 | 69 | 80 | 149 |
| 2024 1 | 50 | 62 | 112 |
| 2023 12 | 46 | 60 | 106 |
| 2023 11 | 60 | 79 | 139 |
| 2023 10 | 67 | 81 | 148 |
| 2023 9 | 61 | 103 | 164 |
| 2023 8 | 87 | 1134 | 1221 |
| 2023 7 | 120 | 105 | 225 |
| 2023 6 | 107 | 118 | 225 |
| 2023 5 | 79 | 105 | 184 |
| 2023 4 | 87 | 122 | 209 |
| 2023 3 | 70 | 143 | 213 |
| 2023 2 | 46 | 67 | 113 |
| 2022 1 | 71 | 108 | 179 |
| 2022 12 | 66 | 145 | 211 |
| 2022 11 | 50 | 220 | 270 |
| 2022 10 | 41 | 221 | 262 |
| 2022 9 | 77 | 242 | 319 |
| 2022 8 | 56 | 293 | 349 |
| 2022 7 | 44 | 709 | 753 |
| 2022 6 | 55 | 179 | 234 |
| 2022 5 | 81 | 85 | 166 |
| 2022 4 | 61 | 62 | 123 |
| 2022 3 | 119 | 86 | 205 |
| 2022 2 | 136 | 65 | 201 |
| 2021 1 | 76 | 46 | 122 |
| 2021 12 | 51 | 42 | 93 |
| 2021 11 | 62 | 46 | 108 |
| 2021 10 | 60 | 43 | 103 |
| 2021 9 | 38 | 36 | 74 |
| 2021 8 | 55 | 47 | 102 |
| 2021 7 | 53 | 47 | 100 |
| 2021 6 | 58 | 28 | 86 |
| 2021 5 | 46 | 50 | 96 |
| 2021 4 | 125 | 53 | 178 |
| 2021 3 | 87 | 46 | 133 |
| 2021 2 | 59 | 43 | 102 |
| 2020 1 | 65 | 27 | 92 |
| 2020 12 | 50 | 25 | 75 |
| 2020 11 | 79 | 30 | 109 |
| 2020 10 | 56 | 31 | 87 |
| 2020 9 | 46 | 19 | 65 |
| 2020 8 | 67 | 12 | 79 |
| 2020 7 | 62 | 16 | 78 |
| 2020 6 | 41 | 21 | 62 |
| 2020 5 | 63 | 25 | 88 |
| 2020 4 | 61 | 36 | 97 |
| 2020 3 | 62 | 18 | 80 |
| 2020 2 | 47 | 28 | 75 |
| 2020 1 | 64 | 30 | 94 |
| 2019 12 | 68 | 32 | 100 |
| 2019 11 | 70 | 34 | 104 |
| 2019 10 | 56 | 31 | 87 |
| 2019 9 | 118 | 45 | 163 |
| 2019 8 | 68 | 22 | 90 |
| 2019 7 | 80 | 33 | 113 |
| 2019 6 | 60 | 22 | 82 |
| 2019 5 | 89 | 28 | 117 |
| 2019 4 | 162 | 53 | 215 |
| 2019 3 | 89 | 28 | 117 |
| 2019 2 | 49 | 16 | 65 |
| 2019 1 | 56 | 27 | 83 |
| 2018 12 | 110 | 45 | 155 |
| 2018 11 | 93 | 19 | 112 |
| 2018 10 | 95 | 32 | 127 |
| 2018 9 | 105 | 27 | 132 |
| 2018 8 | 109 | 57 | 166 |
| 2018 7 | 94 | 39 | 133 |
| 2018 6 | 66 | 27 | 93 |
| 2018 5 | 77 | 36 | 113 |
| 2018 4 | 38 | 26 | 64 |
| 2018 3 | 55 | 26 | 81 |
| 2018 2 | 37 | 11 | 48 |
| 2018 1 | 43 | 9 | 52 |
| 2017 12 | 41 | 12 | 53 |
| 2017 11 | 61 | 18 | 79 |
| 2017 10 | 51 | 11 | 62 |
| 2017 9 | 50 | 11 | 61 |
| 2017 8 | 51 | 8 | 59 |
| 2017 7 | 57 | 18 | 75 |
| 2017 6 | 50 | 7 | 57 |
| 2017 5 | 65 | 15 | 80 |
| 2017 4 | 50 | 13 | 63 |
| 2017 3 | 32 | 14 | 46 |
| 2017 2 | 37 | 9 | 46 |
| 2016 1 | 26 | 10 | 36 |
| 2016 12 | 89 | 8 | 97 |
| 2016 11 | 88 | 14 | 102 |
| 2016 10 | 110 | 16 | 126 |
| 2016 9 | 168 | 8 | 176 |
| 2016 8 | 213 | 10 | 223 |
| 2016 7 | 187 | 34 | 221 |
| 2016 6 | 97 | 0 | 97 |
| 2016 5 | 118 | 0 | 118 |
| 2016 4 | 118 | 0 | 118 |
| 2016 3 | 98 | 0 | 98 |
| 2016 2 | 125 | 0 | 125 |
| 2015 1 | 119 | 0 | 119 |
| 2015 12 | 137 | 0 | 137 |
| 2015 11 | 96 | 0 | 96 |
| 2015 10 | 91 | 0 | 91 |
| 2015 9 | 67 | 0 | 67 |
| 2015 8 | 73 | 0 | 73 |
| 2015 7 | 82 | 0 | 82 |
| 2015 6 | 34 | 0 | 34 |
| 2015 5 | 49 | 0 | 49 |
| 2015 4 | 7 | 0 | 7 |
Mostrar todo
